[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Savara Inc (SVRA)

Savara Inc (SVRA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On June...

SVRA : 5.70 (+3.64%)
Savara Announces Chief Financial and Administrative Officer Transition

-- Dave Lowrance to Step Down as Chief Financial and Administrative Officer -- -- Robert Lutz to Assume Combined Role of Chief Operating and Financial Officer --

SVRA : 5.70 (+3.64%)
Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 5.70 (+3.64%)
Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the ATS 2026 International Conference that is taking...

SVRA : 5.70 (+3.64%)
Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Data Were Presented at the American Thoracic Society (ATS) International Conference 2026 -- -- All Patients Receive Molgramostim During the OL Treatment Period;...

SVRA : 5.70 (+3.64%)
Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

-- Data Were Presented in an Oral Presentation at the American Thoracic Society (ATS) International Conference 2026 --

SVRA : 5.70 (+3.64%)
Savara Reports First Quarter Financial Results and Provides Business Update

Achieved Regulatory Milestones for the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP): ...

SVRA : 5.70 (+3.64%)
Savara's Regulatory Timeline Faces Its First Real Market Test Tomorrow

Barchart Research What to Expect from SVRA Earnings SVRA Generated May 11, 2026 Current Price $5.14 EPS Estimate $$-0.14 Consensus Rating Strong Buy Average Move 5.61% Savara's Regulatory Timeline Faces...

SVRA : 5.70 (+3.64%)
Savara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor Conference

Savara Inc. (Nasdaq: SVRA ) (the “Company”), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that members of the management team...

SVRA : 5.70 (+3.64%)
Savara Announces New Employment Inducement Grant

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to new employees. On April...

SVRA : 5.70 (+3.64%)

Barchart Exclusives

Tim Cook Warns Apple Product Price Hikes Are Unavoidable Due to Higher Chip Costs. What That Means for AAPL Stock.
Apple's outgoing CEO says the iPhone maker has tried to absorb rising memory chip costs but can no longer protect customers from the financial pressure. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.